PHILADELPHIA -- The American Association for Cancer Research (AACR) has granted scholarships to outstanding women in cancer research through the AACR-Women in Cancer Research (WICR) Brigid G. Leventhal Scholar Award in Cancer Research program.
So far this year, 17 women have received a total of $17,000 in scholarships, enabling them to attend AACR Fall Special Conferences and the 95th Annual Meeting. The stipulations of the award are as follows: candidates must be scientists-in-training and first authors of meritorious scientific papers selected for presentation at AACR Fall Special Conferences. They must be members of Women in Cancer Research (WICR), full-time graduate students, medical students, residents, clinical fellows or the equivalent, or postdoctoral fellows. Awards are made possible by grants from AstraZeneca and Novartis Oncology.
Dr. Brigid Grey Leventhal, the award's namesake, was a pioneer among women seeking a career in cancer research. Dr. Leventhal, one of only six women to graduate from the Harvard Medical School class of 1960, began her career in pediatric oncology at the National Cancer Institute. In 1976, she joined the faculty at Johns Hopkins University School of Medicine, where she remained until she herself succumbed to cancer in 1994.
This year's awardees attended the following AACR Conferences: The 95th Annual Meeting, March 27-31, Orlando, Fla.; Advances in Proteomics in Cancer Research, October 6-10, Key Biscayne, Fla.; Frontiers in Cancer Prevention Research, October 16-20, Seattle, Wash.; The Role of Telomeres and Telomerase in Cancer, November 3-7, San Francisco, Calif.; Chromatin, Chromosomes, and Cancer Epigenetics, November 10-14, Waikoloa, Hawaii; Basic, Translational, and Clinical Advances in Prostate Cancer, November 17-21, Bonita Springs, Fla.; Cell Cycle and Cancer: Pathways and Therapies, December 1-5, Fort Lauderdale, Fla.
Winners of the 2004 AACR-WICR Brigid G. Leventhal Scholars in Cancer Research are listed below.
95th Annual Meeting, March 27-31, Orlando, Fla.
Jiyoung Ahn, M.S., Cornell University, Ithaca, N.Y.
Julie L. Blum, B.S., Johns Hopkins University, Baltimore, Md.
Christina M. Coughlin, M.D., Ph.D., Children's Hospital of Philadelphia, Philadelphia, Pa.
Alice E. Guardino, M.D., Ph.D., Stanford University, Stanford, Calif.
Risa Kitagawa, Ph.D., St. Jude Children's Research Hospital, Memphis, Tenn.
Laura E. Klein, Ph.D., Albert Einstein College of Medicine, Bronx, N.Y.
Susan A. Krum, B.S., University of California, Los Angeles, Calif.
Mira A. Rao, M.S., University of British Columbia, Vancouver, BC, Canada.
Cecile M. Ronckers, Ph.D., National Cancer Institute, Rockville, Md.
Kathleen L. Tober, Ph.D., The Ohio State University, Columbus, Ohio
Advances in Proteomics in Cancer Research, October 6-10, Key Biscayne, Fla.
Emily I. Chen, Ph.D., Postdoctoral Fellow, The Scripps Research Institute, La Jolla, Calif.
Frontiers in Cancer Prevention Research, October 16-20, Seattle, Wash.
Sunita B. Jones, Ph.D., Postdoctoral Fellow, Stanford University, Stanford, Calif.
Esther K. Wei, Sc.D., Research Fellow, Harvard School of Public Health, Boston, Mass.
The Role of Telomeres and Telomerase in Cancer, November 3-7, San Francisco, Calif.
Ying Zou, M.D., Graduate Student, UT Southwestern Medical Center, Dallas, Texas
Chromatin, Chromosomes, and Cancer Epigenetics, November 10-14, 2004, Waikoloa, Hawaii
Andrea Varga, Ph.D., Postdoctoral Researcher, Roswell Park Cancer Institute, Buffalo, N.Y.
Basic, Translational, and Clinical Advances in Prostate Cancer, November 17-21, Bonita Springs, Fla.
Christin E. Petre-Draviam, Ph.D., Postdoctoral Fellow, University of Cincinnati, Cincinnati, Ohio.
Cell Cycle and Cancer: Pathways and Therapies, December 1-5, Fort Lauderdale, Fla.
Hannah Wingate, M.S., Graduate Student, UT M. D. Anderson Cancer Center, Houston, Texas.
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.
It is not because things are difficult that we do not dare; it is because we do not dare that they are difficult.